Ketamine Infusion Therapy Cost (2026)

The standard 6-infusion induction protocol typically runs $2,400 to $5,100 total in the US, with a median around $3,000. Per-infusion cost is $350-$850 depending on location and provider. Maintenance infusions afterward run $350-$850 each at variable frequency (every 2-8 weeks typical).

Most US insurance does not cover off-label IV ketamine. Spravato (the FDA-approved esketamine nasal spray) is more frequently covered with prior authorization. For patients with treatment-resistant depression seeking insurance-covered options, Spravato is typically the better financial path. Some HSA/FSA funds can be used for IV ketamine as qualified medical expense when prescribed for a documented diagnosis.

Standard induction is 6 infusions over 2-3 weeks (typically 2-3 per week). Maintenance varies widely by patient response. Common patterns: 1 infusion every 2 weeks initially, gradually extending to every 4-8 weeks as response is sustained. Some patients achieve remission and discontinue maintenance entirely.

Acute antidepressant effects from a single infusion typically last 1-2 weeks. Full induction series produces benefit lasting 2-4 months for many responders. Sustained response often requires ongoing maintenance infusions, similar to how diabetes is managed with ongoing medication rather than cured.

IV ketamine at sub-anesthetic therapeutic doses in a clinical setting has a strong safety profile when properly administered. Common short-term effects include dissociation (expected), transient blood pressure elevation, nausea (10-15%), and grogginess. Serious complications are rare. Abuse risk is low in controlled clinical setting. Long-term high-frequency maintenance carries some bladder dysfunction risk.

Best evidence is for treatment-resistant depression. PTSD evidence is meaningful but less robust than depression evidence. Anxiety as primary diagnosis has limited evidence - ketamine for "anxiety alone" without depression is not well-supported. Some patients with comorbid depression and anxiety see both improve.

Spravato (esketamine) is the FDA-approved nasal spray version, administered in monitored clinic settings under REMS protocol. IV ketamine is the same drug administered intravenously, used off-label. IV ketamine has more years of clinical evidence; Spravato has FDA approval and insurance coverage. Both work via the same NMDA receptor mechanism. Outcomes are broadly comparable.

At-home ketamine (oral or sublingual lozenges prescribed via telehealth platforms like Mindbloom, Better U, Joyous) has less monitoring, less consistent absorption, and less established evidence than clinic IV ketamine. DEA scrutiny in 2023-2026 has tightened legal availability. Some patients respond well; some develop dependence. For most patients with treatment-resistant depression, monitored clinic-based ketamine (IV or Spravato) is the more-evidence-supported path.

Approximately 60-70% of treatment-resistant depression patients show meaningful response (50%+ reduction in depression scores) to a 6-infusion ketamine induction series. About 30-40% achieve full remission. About 30-40% have inadequate or no response. Response rates are higher than continued antidepressant trials for treatment-resistant patients.

Most antidepressants (SSRIs, SNRIs, atypicals) can be continued during ketamine treatment and are typically maintained. Benzodiazepines may reduce ketamine's antidepressant effect and should be tapered or held on infusion days. Lamotrigine may reduce ketamine response. Always coordinate with your prescribing psychiatrist.

Absolute contraindications: active psychosis or schizophrenia, uncontrolled hypertension, history of severe substance abuse disorder, pregnancy, allergy to ketamine. Strong cautions: bipolar disorder (without mood stabilizer coverage), active suicidal ideation without inpatient capability, history of dissociative disorders.

Clinic ketamine pricing reflects: physician time, nursing/monitoring staff, IV supplies, ketamine itself (relatively inexpensive), clinic overhead, the 60-90 minute time commitment per session, and the cash-pay nature of off-label treatment. Spravato (FDA-approved) is similarly expensive cash but more often insurance-covered, making it the more affordable path for many patients.